Accordingly, simultaneous inhibition of the mTOR pathway and CDK6 activity by palbociclib exerted greater antitumor activity than either treatment alone, both in vitro in human T cell acute lymphoblastic leukemia/lymphoma and in vivo [45]. The gene discussed is MTOR; the disease is T-cell acute lymphoblastic leukemia.